176 related articles for article (PubMed ID: 33758232)
1. Low cardiac dose and neutrophil-to-lymphocyte ratio predict overall survival in inoperable esophageal squamous cell cancer patients after chemoradiotherapy.
Ho YC; Lai YC; Lin HY; Ko MH; Wang SH; Yang SJ; Lin PJ; Chou TW; Hung LC; Huang CC; Chang TH; Lin JB; Lin JC
Sci Rep; 2021 Mar; 11(1):6644. PubMed ID: 33758232
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.
Zhou XL; Li YQ; Zhu WG; Yu CH; Song YQ; Wang WW; He DC; Tao GZ; Tong YS
Sci Rep; 2017 Feb; 7():42581. PubMed ID: 28195186
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil to Lymphocyte Ratio as Predictor of Treatment Response in Esophageal Squamous Cell Cancer.
Barbetta A; Nobel TB; Sihag S; Hsu M; Tan KS; Bains MS; Isbell JM; Janjigian YY; Wu AJ; Bott MJ; Jones DR; Molena D
Ann Thorac Surg; 2018 Sep; 106(3):864-871. PubMed ID: 29738752
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of neutrophil-lymphocyte ratio in operable esophageal squamous cell carcinoma.
Duan H; Zhang X; Wang FX; Cai MY; Ma GW; Yang H; Fu JH; Tan ZH; Meng YQ; Fu XY; Ma QL; Lin P
World J Gastroenterol; 2015 May; 21(18):5591-7. PubMed ID: 25987784
[TBL] [Abstract][Full Text] [Related]
5. Prechemotherapy neutrophil : lymphocyte ratio is superior to the platelet : lymphocyte ratio as a prognostic indicator for locally advanced esophageal squamous cell cancer treated with neoadjuvant chemotherapy.
Ji WH; Jiang YH; Ji YL; Li B; Mao WM
Dis Esophagus; 2016 Jul; 29(5):403-11. PubMed ID: 25625421
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil:lymphocyte ratio as a simple and novel biomarker for prediction of locoregional recurrence after chemoradiotherapy for squamous cell carcinoma of the anus.
Toh E; Wilson J; Sebag-Montefiore D; Botterill I
Colorectal Dis; 2014 Mar; 16(3):O90-7. PubMed ID: 24148256
[TBL] [Abstract][Full Text] [Related]
7. Cardiac radiation dose predicts survival in esophageal squamous cell carcinoma treated by definitive concurrent chemotherapy and intensity modulated radiotherapy.
Pao TH; Chang WL; Chiang NJ; Chang JS; Lin CY; Lai WW; Tseng YL; Yen YT; Chung TJ; Lin FC
Radiat Oncol; 2020 Sep; 15(1):221. PubMed ID: 32962730
[TBL] [Abstract][Full Text] [Related]
8. High neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predict poor survival in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy.
Ke TM; Lin LC; Huang CC; Chien YW; Ting WC; Yang CC
Medicine (Baltimore); 2020 Apr; 99(17):e19877. PubMed ID: 32332656
[TBL] [Abstract][Full Text] [Related]
9. Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
Hsieh HY; Hsu CP; Yeh HL; Chuang CY; Lin JF; Chang CF
Kaohsiung J Med Sci; 2018 May; 34(5):281-289. PubMed ID: 29699635
[TBL] [Abstract][Full Text] [Related]
10. The Preoperative Neutrophil-To-Lymphocyte Ratio Is a Novel Immune Parameter for the Prognosis of Esophageal Basaloid Squamous Cell Carcinoma.
Xiao Q; Zhang B; Deng X; Wu J; Wang H; Wang Y; Wang W
PLoS One; 2016; 11(12):e0168299. PubMed ID: 27959959
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of lymphocyte-to-monocyte ratio (LMR) and neutrophil-to-lymphocyte ratio (NLR) in patients with oesophageal cancer undergoing concurrent chemoradiotherapy.
Li KJ; Xia XF; Su M; Zhang H; Chen WH; Zou CL
BMC Cancer; 2019 Oct; 19(1):1004. PubMed ID: 31655563
[TBL] [Abstract][Full Text] [Related]
12. Elevated Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio after First Cycle of Chemotherapy and Better Survival in Esophageal Cancer Patients Receiving Concurrent Chemoradiotherapy.
Tseng RH; Lai KM; Tsai CY; Yan SL
Curr Oncol; 2022 Nov; 29(11):8825-8834. PubMed ID: 36421347
[No Abstract] [Full Text] [Related]
13. Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma.
Lin WC; Ding YF; Hsu HL; Chang JH; Yuan KS; Wu ATH; Chow JM; Chang CL; Chen SU; Wu SY
Cancer; 2017 Oct; 123(20):3904-3915. PubMed ID: 28608916
[TBL] [Abstract][Full Text] [Related]
14. Hematologic Markers as Prognostic Factors in Nonmetastatic Esophageal Cancer Patients under Concurrent Chemoradiotherapy.
Wu YF; Chu SC; Chang BS; Cheng YT; Wang TF
Biomed Res Int; 2019; 2019():1263050. PubMed ID: 30834254
[TBL] [Abstract][Full Text] [Related]
15. Tumor length assessed by miniprobe endosonography can predict the survival of the advanced esophageal squamous cell carcinoma with stricture receiving concurrent chemoradiation.
Chang WL; Lin FC; Yen CJ; Cheng H; Lai WW; Yang HB; Sheu BS
Dis Esophagus; 2011 Nov; 24(8):590-5. PubMed ID: 21539673
[TBL] [Abstract][Full Text] [Related]
16. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
Cheng JC; Graber MS; Hsu FM; Tsai CL; Castaneda L; Lee JM; Chang DT; Koong AC
Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques.
Yen YC; Chang JH; Lin WC; Chiou JF; Chang YC; Chang CL; Hsu HL; Chow JM; Yuan KS; Wu ATH; Wu SY
Cancer; 2017 Jun; 123(11):2043-2053. PubMed ID: 28152166
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of pretreatment inflammatory biomarkers in primary small cell carcinoma of the esophagus.
Wang N; Li X; Luo H; Sun Y; Zheng X; Fan C; Wang H; Ye K; Ge H
Thorac Cancer; 2019 Oct; 10(10):1913-1918. PubMed ID: 31389159
[TBL] [Abstract][Full Text] [Related]
19. Good prediction of treatment responses to neoadjuvant chemoradiotherapy for esophageal cancer based on preoperative inflammatory status and tumor glucose metabolism.
Li C; Lin JW; Yeh HL; Chuang CY; Chen CC
Sci Rep; 2021 Jun; 11(1):11626. PubMed ID: 34078965
[TBL] [Abstract][Full Text] [Related]
20. Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy.
Davuluri R; Jiang W; Fang P; Xu C; Komaki R; Gomez DR; Welsh J; Cox JD; Crane CH; Hsu CC; Lin SH
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):128-135. PubMed ID: 28816138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
